12:00 AM
 | 
Sep 08, 2008
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Staccato loxapine: Phase III data

Top-line data from a double-blind, U.S. Phase III trial in 344 patients showed that 10 mg of inhaled AZ-004 met all primary and secondary endpoints, and 5 mg met the primary but not all secondary endpoints. At 2 hours after the first dose, patients receiving 5 and 10 mg AZ-004 had a change...

Read the full 243 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >